Search
Modality profile: Radiotherapies at #ASCO23 with Dr. Phil Kantoff
Convergent Therapeutics CEO Phil Kantoff describes the use of targeted radiotherapies against cancer. #ASCO23
Jun 4, 2023
Antibody-drug conjugates at #ASCO23 with Seagen’s David Epstein
Seagen CEO David Epstein talks about moving antibody-drug conjugates into broader indications at #ASCO23.
Jun 4, 2023
The latest on lung cancer advances at #ASCO23 from one of the field’s leading experts
Dr. Jack West walks us through what lung cancer data he is interested in seeing at #ASCO23.
Jun 3, 2023
Dissecting the TIGIT battleground at #ASCO23
Arcus Biosciences CEO Terry Rosen describes the ARC-7 TIGIT data update that was presented at #ASCO23.
Jun 3, 2023
Watching cell therapy innovation at #ASCO23.
Paul Rennert of Aleta Biotherapeutics gives a rundown on the latest in cell therapies and other modalities ahead of #ASCO23.
Jun 2, 2023
.png){kind=logo}
